Indian equity benchmark indices concluded June 5, 2026, on a largely flat note following a volatile trading session. Market sentiment was influenced by ongoing geopolitical tensions and anticipation ahead of the Reserve Bank of India's monetary policy announcement. The BSE Sensex saw a modest rise of 13.94 points, closing at 74,360.01, while the NSE Nifty50 gained 10.95 points to end the day at 23,416.55. Several prominent companies also traded ex-dividend, including Reliance Industries, HDFC Asset Management Company, ICICI Prudential Life, Cipla, and Bank of Baroda.
Key Companies Making Headlines
Here’s a closer look at the Indian stocks that were in the spotlight on June 5, 2026:
Rajesh Exports Addresses SEBI Concerns
Gold exporter Rajesh Exports came under scrutiny after the market regulator, SEBI, raised allegations regarding the source of its revenue. Chairman Rajesh Mehta affirmed the accuracy of the company's financial disclosures, explaining to Reuters that SEBI's concerns stemmed from differing methods of revenue calculation that did not account for consolidated revenue, particularly from its overseas subsidiaries like Valcambi SA. SEBI had previously alleged that 97-99 percent of the jeweller’s revenue originated from these foreign entities.
Hindalco Industries Expands Eternia Windows
Aditya Birla Group's metals flagship, Hindalco Industries, is expanding its market presence for its high-performance aluminium window systems under the 'Eternia' brand. The company announced the inauguration of its flagship Eternia experience centre in Lajpat Nagar, New Delhi. This expansion is complemented by strengthening its manufacturing capabilities in North India, notably with its facility in Bilaspur.
Aurobindo Pharma Receives USFDA Approval
Pharmaceutical giant Aurobindo Pharma has secured final approval from the US Food and Drug Administration (USFDA) to manufacture and market Tofacitinib Tablets, in both 5 mg and 10 mg strengths. These tablets are deemed bioequivalent and therapeutically equivalent to the reference listed drug, Xeljanz Tablets, manufactured by PF Prism CV. The product will be produced at APL Healthcare Unit IV and is slated for immediate launch.
IndiGo Adjusts International Network
InterGlobe Aviation, the parent company of IndiGo, has announced temporary adjustments to a select segment of its international flight network. Effective from July 1 and July 3, 2026, until September 30, 2026, the airline will temporarily suspend operations to Langkawi, Krabi, Ho Chi Minh City, Hong Kong, Shanghai, and Siem Reap. Bookings for these affected services are expected to resume starting October 1, 2026.
HDFC AMC Restricts Gold ETF Subscriptions
HDFC Asset Management Company, a prominent mutual fund sponsor, has temporarily imposed restrictions on lump-sum subscriptions for its Gold ETF and Gold ETF Fund of Fund (FoF). The company cited prevailing economic and market conditions as the reason for this temporary measure.
Lupin Gains USFDA Approval for Ranluspec
Pharmaceutical major Lupin has received approval from the USFDA for Ranluspec (ranibizumab-hkdz), an interchangeable biosimilar to Genentech's Lucentis. Notably, Ranluspec is the only interchangeable biosimilar ranibizumab approved in the United States available in both vial and pre-filled syringe (PFS) presentations, offering flexibility in administration.
CG Power Commissions New Facility
Capital goods company CG Power and Industrial Solutions has commissioned its new extra-high-voltage (EHV) switchgear manufacturing facility in Nashik, Maharashtra. This new facility complements its existing S3 Unit-I manufacturing unit at Ambad, Nashik, which specializes in producing EHV circuit breakers ranging from 33kV to 800kV.
Ola Electric Mobility Raises Funds
Electric vehicle manufacturer Ola Electric Mobility successfully raised Rs 780 crore through a qualified institutional placement (QIP). The QIP was significantly oversubscribed by 56 percent. The company's committee approved the allocation of 21.76 crore equity shares at an issue price of Rs 35.86 per share, which includes a premium of Rs 25.86 per share.
AvenuesAI Receives UAE Central Bank Approval
AvenuesAI's step-down subsidiary, Avenues World FZ LLC, has received in-principle approval from the Central Bank of the UAE. This approval grants the company a Retail Payment Services Category III Licence, in line with the Retail Payment Services and Card Schemes Regulation, marking a significant step for its operations in the region.